Phathom Pharmaceuticals, Inc.
HealthcareNASDAQ:PHAT · NASDAQ Global Select
+$0.10 today
Vol 0.55M · Avg 1.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
50.5%
avg 58.2%
ROIC
-125.2%
avg -92.3%
ROA
-85.4%
avg -85.8%
Analysis
ROE is currently the strongest return metric at 50.5% versus its period average of 58.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David A. Socks | Co-Founder | $1.95M | — | 51 | $19,500.00 | 0.02% |
Azmi Nabulsi | Co-Founder | $1.95M | — | 66 | $312,590.00 | 0.39% |
Steven L. Basta | Chief Executive Officer, President & Director | $1.17M | — | 60 | $379,592.00 | 0.48% |
Anne Marie Cook | Chief Legal Officer & Corporate Secretary | $663,406.00 | — | 64 | $90,195.00 | 0.11% |
Sanjeev Narula | Chief Financial & Business Officer | $644,285.00 | — | 64 | $226,715.00 | 0.28% |
Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | — | — | — | — | — |
Eric Sciorilli | Director of Business Development & Investor Relations | — | — | — | — | — |
Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | — | — | — | $2.02M | 2.53% |
Robert Breedlove | Vice President of Finance & Principal Accounting Officer | — | — | — | $62,858.00 | 0.08% |
Nancy R. Phelan | Senior Vice President of Marketing & Analytics | — | — | 57 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$26,804.45
Net Sentiment
$26,804.45
Net selling
Most Active
Breedlove Robert Charles
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $26,804.45 over the last 12 months. That adds up to net selling of $26,804.45. Breedlove Robert Charles was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Who manages PHAT?
Phathom Pharmaceuticals, Inc. (PHAT) lists 10 active executives. The top listed executive is David A. Socks, Co-Founder.
Are PHAT insiders buying or selling?
Recent insider activity shows net selling of $30.46M.
Explore More
Continue the stock analysis
Jump to another research area for this company.